EXPERT REVIEW OF ANTICANCER THERAPY Journal
Overview
publication venue for
- Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy 2023
- Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer 2022
- The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer 2014
- Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts 2012
- Erectile dysfunction after robot-assisted radical prostatectomy 2010
- Robotic-assisted laparoscopic radical prostatectomy: a report of the current state 2007
- Surgical therapy of genitourinary cancers 2007
- Motexafin gadolinium: a novel radiosensitizer for brain tumors 2007
- Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors Part 5: Apoptosis and cell cycle 2005
- Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors - Part 4: p53 signaling pathway 2005
- Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. 2004
- Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways. 2003
- Chemotherapy for the treatment of metastatic brain tumors. 2002
Research
category
- ONCOLOGY Web of Science Category
Identity
International Standard Serial Number (ISSN)
- 1473-7140
Electronic International Standard Serial Number (EISSN)
- 1744-8328
Other
journal abbreviation
- EXPERT REV ANTICANC
- Expert Rev Anticancer Ther